Back to funds
View filing
Decheng Capital LLC
hedge fundUpdated 28 days agoManaged by Decheng Capital Llc • Latest filing Q2 2026
Portfolio value
$731.7M
Q2 2026
Filings
11
Quarterly 13F history
Top-10 concentration
100.0%
Weight of largest holdings
Annualized return
44.1%
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 11 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q4 2023 | $357.9M |
| Q1 2024 | $745.6M |
| Q2 2024 | $326.3M |
| Q3 2024 | $422.2M |
| Q4 2024 | $466.2M |
| Q1 2025 | $356.5M |
| Q2 2025 | $396M |
| Q3 2025 | $573.2M |
| Q4 2025 | $743.4M |
| Q1 2026 | $661.3M |
| Q2 2026 | $731.7M |
Top holdings
14 positions as of Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | C CGON CG ONCOLOGY INC | $452.7M | 6.37M | 61.87% | — |
| 2 | N NUVB Nuvation Bio Inc. | $147.4M | 25.95M | 20.15% | — |
| 3 | ? N/A AARDVARK THERAPEUTICS INC | $22.6M | 3.92M | 3.08% | — |
| 4 | A ACRS Aclaris Therapeutics, Inc. | $21.4M | 4.04M | 2.92% | — |
| 5 | ? N/A Upstream Bio Inc. | $18.9M | 2.72M | 2.58% | — |
| 6 | R RCUS Arcus Biosciences, Inc | $14.3M | 464.8K | 1.96% | — |
| 7 | ? N/A Equillium Inc. | $14.2M | 4.45M | 1.94% | — |
| 8 | R RVMDW REVOLUTION MEDICINES INC(NSM) | $9.9M | 52.7K | 1.35% | — |
| 9 | L LYEL Lyell Immunopharma, Inc. | $9.7M | 692.0K | 1.33% | — |
| 10 | B BYSI BeyondSpring Inc. | $6.7M | 3.80M | 0.91% | — |
| 11 | ? N/A Zentalis Pharmaceuticals Inc. | $6.4M | 1.32M | 0.88% | — |
| 12 | N NAMSW NEWAMSTERDAM PHARMA CO NV | $6M | 176.9K | 0.82% | — |
| 13 | Q QUBT Pyxis Oncology, Inc (formerly Apexigen) | $984K | 326.8K | 0.13% | — |
| 14 | T TNGX TANGO THERAPEUTICS INC | $625K | 20.0K | 0.09% | — |